Minor Blood Group Systems: Kell, Duffy, Kidd, and Beyond

Introduction

ABO and Rh get most of the attention in blood banking, and for good reason. But red blood cells carry hundreds of other antigens, organized into more than 40 additional blood group systems recognized by the International Society of Blood Transfusion. Most of these rarely cause trouble. A handful do, and they can cause transfusion reactions or fetal disease just as serious as anything seen in the Rh system.

This article covers the minor blood group systems that matter most in practice: Kell, Duffy, Kidd, and briefly MNS and Lewis. These four or five systems account for the large majority of clinically significant non-ABO, non-Rh antibodies encountered in transfusion medicine .

Why "Minor" Doesn't Mean Unimportant

The word "minor" here refers to how often these antigens cause problems compared to ABO and Rh, not how mild the problems are. Kell alloimmunization, for instance, can cause fetal anemia severe enough to require in-utero transfusion. Kidd antibodies can trigger delayed hemolytic transfusion reactions days after a seemingly uneventful transfusion. Both deserve careful attention in the right clinical setting.

The Kell Blood Group System

Antigens and Genetics

Kell is a large system with 38 recognized antigens, but two matter most: K (Kell 1) and k (Kell 2, sometimes called Cellano). These are the products of two co-dominant alleles at the KEL gene. Most people are k-positive; K-positive people are a minority, at about 9% in populations of European descent, and considerably less common in African and Asian populations [1,2].

Kell antigens sit on a large transmembrane protein that is fully developed on red cells as early as 10 weeks of fetal life [1]. This early expression is part of why Kell alloimmunization in pregnancy can strike hard and early.

Why K Is So Immunogenic

Kell ranks third after ABO and RhD in its ability to provoke an immune response [1,2]. Even a small mismatched transfusion can trigger anti-K production in a K-negative recipient.

Kell and Fetal Anemia

Most hemolytic disease of the fetus and newborn (HDFN) works the way Rh disease does: maternal antibody crosses the placenta and destroys mature fetal red cells. Kell is different. Kell antigens are expressed on early red cell precursors in the bone marrow, not just on mature cells. Anti-K antibodies can suppress red cell production at this early stage, causing fetal anemia that is often out of proportion to the antibody titer and to any visible signs of hemolysis [5]. This makes Kell-related fetal anemia harder to predict from titers alone, and closer fetal surveillance (typically MCA-PSV Doppler) is used once anti-K is identified in a pregnant patient.

McLeod Syndrome

A rare group of people lack the Kx protein, a structural support molecule that normal Kell expression depends on. This results in the McLeod phenotype, where Kell antigens are severely weakened. In some cases, this presents as McLeod syndrome, a multisystem condition involving muscle weakness, cardiac problems, and neurological symptoms, alongside abnormally shaped red cells (acanthocytes) [17,20]. Separately, individuals with the Kell-null (K0) phenotype lack all Kell antigens entirely; however, they maintain high levels of Kx and do not suffer from McLeod syndrome [21]. Both conditions are rare, but serve as useful examples of how a single blood group protein can have effects that reach well beyond transfusion medicine.

The Duffy Blood Group System

Antigens and Genetics

The Duffy system is built around two antigens, Fya and Fyb, encoded by the ACKR1 gene (formerly called DARC) on chromosome 1 [6]. A single nucleotide change distinguishes the two alleles.

A Blood Group That Doubles as a Malaria Receptor

Duffy antigens are not just markers for blood typing. The Duffy protein also functions as a receptor for inflammatory chemokines, and, critically, it is the doorway Plasmodium vivax uses to invade red blood cells [3,6].

A mutation in the gene's promoter region silences Duffy expression on red cells entirely, producing the Fy(a−b−) or Duffy-null phenotype. This mutation is common in populations of African ancestry, reaching near-fixation in parts of West Africa, where more than 95% of people are Duffy-null [9]. Because the parasite cannot dock without the receptor, Duffy-null individuals are highly resistant to P. vivax blood-stage infection [6,7]. This is one of the clearer examples in human genetics of a blood group variant persisting because it confers protection against infectious disease. Resistance is not absolute; rare cases of vivax infection in Duffy-negative individuals have been reported in some African regions [9].

Clinical Significance in Transfusion and Pregnancy

Despite the malaria connection, anti-Fya and anti-Fyb are clinically significant in an ordinary transfusion sense too. They are IgG antibodies capable of causing hemolytic transfusion reactions, and they can cross the placenta to cause HDFN, though this is generally milder than Kell- or Rh-related disease [3].

The Kidd Blood Group System

Antigens and Genetics

Kidd has two main antithetical antigens, Jka and Jkb, encoded by SLC14A1 on chromosome 18 [10,11]. This gene doesn't just sit quietly on red cells: it encodes a urea transporter, present on red blood cells and in the kidney's vasa recta, where it helps the kidney concentrate urine [11]. People with the rare Jk(a−b−) phenotype lack this transporter and have a mildly reduced ability to concentrate urine, though this causes no other health problems [11].

The Delayed Hemolytic Transfusion Reaction Problem

Kidd antibodies have a well-earned reputation as troublemakers in the blood bank. Their concentration in plasma tends to fall below detectable levels between exposures, so a patient's antibody screen can come back negative even though they are sensitized. Give that same patient Jka-positive blood again, and a rapid anamnestic (memory) response kicks in days later, causing a delayed hemolytic transfusion reaction (DHTR).

Kidd antibodies are estimated to cause more than a third of all delayed hemolytic transfusion reactions, some of them severe [11]. A negative antibody screen at the time of transfusion does not rule out a prior Kidd sensitization. A documented case of a delayed reaction driven by anti-Jka illustrates exactly this pattern, where antibodies undetected on initial screening surfaced only after re-transfusion [13].

Typical signs of a DHTR, usually appearing 3–14 days post-transfusion:

• Unexplained drop in hemoglobin after an initially adequate response
• Low-grade fever
• Rising bilirubin and LDH
• Positive DAT on repeat testing
• Occasionally hemoglobinuria, though intravascular hemolysis is less common than with acute reactions

Kidd antibodies rarely cause severe HDFN, though mild cases occur [10,11].

The MNS Blood Group System

MNS antigens (M, N, S, s, and the near-universal U) sit on two glycophorin proteins, GYPA and GYPB, on chromosome 4 [19]. Anti-M and anti-N are usually cold-reactive antibodies of limited clinical concern, but anti-S and anti-s are IgG antibodies capable of causing hemolytic transfusion reactions and, occasionally, HDFN [19]. MNS antigens are included in extended antigen matching panels for chronically transfused patients alongside Kell, Duffy, and Kidd [14,17].

The Lewis Blood Group System

Lewis antigens (Lea, Leb) are unusual: they are not made directly on red cells but are absorbed onto the cell surface from plasma. Lewis antibodies are typically IgM, react best at cold temperatures, and are usually of little clinical consequence, so compatible blood does not routinely need to be Lewis-antigen negative [18].

Clinical Significance

Antibody Screening and Identification

A routine antibody screen uses reagent red cells carrying a panel of clinically significant antigens, including K, Fya, Fyb, Jka, Jkb, S, and s, alongside the Rh antigens. If a patient's plasma reacts, an antibody identification panel narrows down which specific antibody is present. This workup is what catches Kell, Duffy, and Kidd antibodies before a mismatched unit is issued.

Delayed Hemolytic Transfusion Reactions: General Workup

Regardless of which system is responsible, a suspected DHTR is worked up with:

1. Repeat direct antiglobulin test (DAT)
2. Repeat antibody screen and identification
3. Bilirubin, LDH, and haptoglobin
4. Hemoglobin trend over the days following transfusion
5. Review of transfusion history for prior exposures

Extended Antigen Matching in Chronically Transfused Patients

Patients who need many transfusions over a lifetime, most notably those with sickle cell disease and transfusion-dependent thalassemia, are at high risk of alloimmunization simply because of repeated antigen exposure. Left unmatched, alloimmunization rates in sickle cell disease can reach as high as 50%; matching for Rh (C, c, E, e) and K alone brings this down to roughly 5–24% [15].

To combat this, the 2020 American Society of Hematology (ASH) guidelines strongly recommend prophylactic matching for Rh (C/c, E/e) and Kell (K) antigens for all sickle cell patients from their very first transfusion, before any antibodies develop [22]. Once a patient has developed one or more alloantibodies, guidelines recommend extending that match further to include Kidd, Duffy, and MNS (S, s) antigens [14,17,22]. Programs using this broader extended match have reported alloimmunization rates as low as 7% [15].

Typical extended matching panel for a chronically transfused patient with a prior alloantibody:

• Rh: D, C, c, E, e
• Kell: K
• Kidd: Jka, Jkb
• Duffy: Fya, Fyb
• MNS: S, s

Furthermore, ASH now recommends molecular genotyping over traditional serologic testing to determine a patient's baseline red cell antigen profile [22]. Genotyping is more accurate in people who have been recently transfused (whose blood is a mixture of their own and donor cells) and can detect critical genetic variants that serology misses, such as the ACKR1 GATA mutation in the Duffy system [23].

Quick Reference

Frequently Asked Questions (FAQs)

What's the difference between a "major" and "minor" blood group system?

ABO and Rh are considered major because they are tested in every routine blood typing and because mismatches there cause the most severe and most common reactions. Minor systems, including Kell, Duffy, Kidd, and MNS, are not part of routine typing but can still cause serious transfusion reactions or fetal disease in specific patients, usually once an antibody has already been detected on a screen.

Why does Duffy blood type matter for malaria?

The Duffy protein is the docking site Plasmodium vivax uses to enter red blood cells. People who lack Duffy antigens entirely, a trait common in populations of African ancestry, are largely resistant to this form of malaria because the parasite has no way in. This is a rare case where a blood group trait has a direct, well-documented survival advantage.

Why are Kidd antibodies so hard to catch on a routine screen?

Kidd antibody levels in the blood tend to fall over time between exposures, sometimes below what standard testing can detect. A patient can test negative on an antibody screen and still be sensitized. If they then receive Kidd-antigen-positive blood again, a strong memory response can trigger a delayed hemolytic transfusion reaction days later.

Who needs extended antigen matching for transfusions?

Patients who require many transfusions over their lifetime, most often people with sickle cell disease or transfusion-dependent thalassemia, benefit most. Extended matching across Rh, Kell, Kidd, Duffy, and MNS antigens substantially lowers their risk of developing new antibodies, which in turn makes it easier to find compatible blood for them in the future.

Can Kell antibodies affect a pregnancy even without much visible hemolysis?

Yes. Kell antigens appear very early on red cell precursors in the fetal bone marrow, so anti-K antibodies can suppress red cell production directly rather than only destroying mature cells. This means fetal anemia from Kell sensitization can be more severe than the antibody titer alone would suggest, which is why any Kell-sensitized pregnancy gets close monitoring.

Do I need to worry about Lewis antibodies before a transfusion?

Generally, no. Lewis antibodies are usually IgM, react best at cold temperatures, and rarely cause clinically significant hemolysis. Compatible blood does not routinely need to be Lewis-antigen negative, unlike Kell-, Duffy-, or Kidd-antigen-negative blood in a sensitized patient.

Glossary of Related Medical Terms

• Alloimmunization — Development of antibodies against antigens from another person of the same species, typically after transfusion or pregnancy.
• Anamnestic response — A rapid, strong antibody response on re-exposure to an antigen the immune system has seen before.
• Antithetical antigens — Paired antigens encoded by different alleles of the same gene (e.g., Fya and Fyb), such that a person typically expresses one, the other, or both.
• Delayed hemolytic transfusion reaction (DHTR) — A transfusion reaction that appears days after transfusion, usually caused by an anamnestic antibody response to an antigen the patient was previously sensitized to.
• Direct antiglobulin test (DAT) — A lab test that detects antibody already bound to red blood cells in the body.
• Extended antigen matching — Matching donor and recipient blood beyond ABO/Rh, across systems like Kell, Kidd, Duffy, and MNS, to reduce alloimmunization risk in patients needing repeated transfusions.
• Glycophorin — A red cell membrane protein that carries certain blood group antigens, including M, N, S, and s.
• Hemolytic disease of the fetus and newborn (HDFN) — Destruction of fetal or newborn red cells by maternal antibodies that crossed the placenta.
• Phenotype (in blood banking) — The observed pattern of antigens present on a person's red blood cells, determined by lab testing.
• Urea transporter — A membrane protein that moves urea across cell membranes; in the Kidd system, this same protein carries the Jka/Jkb antigens.

References

1. Rosenkrans D, Zubair M, Doyal A. Rh Blood Group System. [Updated 2023 Aug 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK594252/
2. Maheshwari A, Zubair M, Maheshwari A. Kell Blood Group System. [Updated 2024 Oct 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK609095/
3. Kell antigen screening enhances maternal-fetal and transfusion care. (2025). Policy Research Journal, as summarized in Rare Disease Advisor. https://www.rarediseaseadvisor.com/news/kell-antigen-screening-enhances-maternal-fetal-transfusion-care/
4. Duffy blood group. (n.d.). In ScienceDirect Topics. https://www.sciencedirect.com/topics/immunology-and-microbiology/blood-group-kell-system
5. Vaughan, J. I., Manning, M., Warwick, R. M., Letsky, E. A., Murray, N. A., & Roberts, I. A. (1998). Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. The New England journal of medicine, 338(12), 798–803. https://doi.org/10.1056/NEJM199803193381204
6. Zimmerman, P. A., Ferreira, M. U., Howes, R. E., & Mercereau-Puijalon, O. (2013). Red blood cell polymorphism and susceptibility to Plasmodium vivax. Advances in parasitology, 81, 27–76. https://doi.org/10.1016/B978-0-12-407826-0.00002-3
7. Miller, L. H., Mason, S. J., Clyde, D. F., & McGinniss, M. H. (1976). The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. The New England journal of medicine, 295(6), 302–304. https://doi.org/10.1056/NEJM197608052950602
8. Kano, F.S., de Souza, A.M., de Menezes Torres, L. et al. Susceptibility to Plasmodium vivax malaria associated with DARC (Duffy antigen) polymorphisms is influenced by the time of exposure to malaria. Sci Rep 8, 13851 (2018). https://doi.org/10.1038/s41598-018-32254-z
9. Cavasini, C. E., de Mattos, L. C., Couto, A. A., Couto, V. S., Gollino, Y., Moretti, L. J., Bonini-Domingos, C. R., Rossit, A. R., Castilho, L., & Machado, R. L. (2007). Duffy blood group gene polymorphisms among malaria vivax patients in four areas of the Brazilian Amazon region. Malaria journal, 6, 167. https://doi.org/10.1186/1475-2875-6-167
10. Lawicki, S., Covin, R. B., & Powers, A. A. (2017). The Kidd (JK) Blood Group System. Transfusion medicine reviews, 31(3), 165–172. https://doi.org/10.1016/j.tmrv.2016.10.003
11. Kidd blood group system. (n.d.). In ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-group-kidd-system
12. Dean L. Blood Groups and Red Cell Antigens [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2005. Chapter 10, The Kidd blood group. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK2272/
13. Canadian Blood Services. (2024). Serological best practices. Professional Education. https://professionaleducation.blood.ca/en/transfusion/best-practices/serological-best-practices
14. Tanhehco, Y. C. (2022). Transfusion therapy in sickle cell disease. Annals of Blood, 7, 12.
15. Linder, G. E., & Chou, S. T. (2021). Red cell transfusion and alloimmunization in sickle cell disease. Haematologica, 106(7), 1805–1815. https://doi.org/10.3324/haematol.2020.270546
16. Canadian Blood Services. (2024). Phenotype matching and storage age of blood for sickle cell patients: A review and recommendations for transfusion practice. Professional Education.
17. Smart, E., Armstrong, B. and Reviewer for Second Edition: Edmond Lee (2020), Blood group systems. VOXS, 15: 123-150. https://doi.org/10.1111/voxs.12593
18. Blood group MNSs system. (n.d.). In ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/blood-group-mnss-system
19. MNS blood group system. (2023). Anthroholic. https://anthroholic.com/mns-blood-group-system
20. Jung, H. H., Danek, A., & Walker, R. H. (2011). Neuroacanthocytosis syndromes. Orphanet journal of rare diseases, 6, 68. https://doi.org/10.1186/1750-1172-6-68
21. Daniels, G. (2013). Human Blood Groups (3rd ed.). Wiley-Blackwell.
22. Chou, S. T., Alsawas, M., Fasano, R. M., Field, J. J., Hendrickson, J. E., Howard, J., Kameka, M., Kwiatkowski, J. L., Pirenne, F., Shi, P. A., Stowell, S. R., Thein, S. L., Westhoff, C. M., Wong, T. E., & Akl, E. A. (2020). American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood advances, 4(2), 327–355. https://doi.org/10.1182/bloodadvances.2019001143
23. Fasano, R. M., & Chou, S. T. (2016). Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications. Transfusion medicine reviews, 30(4), 197–201. https://doi.org/10.1016/j.tmrv.2016.05.011